Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 3, 2004. The report serves as a notification of changes in directors' interests in the company's Ordinary Shares.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is limited to corporate governance disclosures regarding share ownership.
Material Changes
On February 2, 2004, Abacus (GSK) Trustees Limited, acting as trustee for the GlaxoSmithKline Employee Trust ("GSK Trust"), transferred 4,550 Ordinary shares to participants in the SmithKline Beecham Employee Share Option Plan 1991. The company was advised of this transaction on February 3, 2004.
Outlook, Risks, and Management Commentary
The filing contains no guidance, outlook, or management commentary regarding future performance. It notes that the GSK Trust is a discretionary trust where all current and former employees are potential beneficiaries. Consequently, three directors—Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe—hold an interest in the shares held by the GSK Trust in the same capacity as other employees.
Investor Verification Points
- Verify the total number of shares held by the GSK Trust following the transfer of 4,552 shares.
- Confirm the specific shareholding details of directors Dr J-P Garnier, Dr T Yamada, and Mr J D Coombe relative to the trust.
- Review the terms of the SmithKline Beecham Employee Share Option Plan 1991 to understand the vesting conditions for the transferred shares.